Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $64.75, but opened at $65.04. Ultragenyx Pharmaceutical shares last traded at $65.98, with a volume of 171,780 shares traded.

RARE has been the topic of several research analyst reports. Credit Suisse Group AG reaffirmed a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 25th. Canaccord Genuity reaffirmed a “buy” rating and set a $120.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, July 15th. Jefferies Group reiterated a “buy” rating and set a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, May 10th. Leerink Swann reiterated an “outperform” rating and set a $85.00 price objective (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 10th. Finally, Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday, April 28th. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $98.09.

The company’s market capitalization is $2.59 billion. The stock’s 50-day moving average is $54.70 and its 200-day moving average is $61.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.29) by $0.06. During the same quarter last year, the business posted ($0.63) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.84) EPS for the current fiscal year.

In other news, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $52.68, for a total transaction of $34,189.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the sale, the chief executive officer now owns 526,704 shares in the company, valued at $31,575,904.80. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in RARE. Dimensional Fund Advisors LP increased its position in shares of Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares in the last quarter. Jennison Associates LLC increased its position in shares of Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $1,010,000. GSA Capital Partners LLP increased its position in shares of Ultragenyx Pharmaceutical by 12.2% in the fourth quarter. GSA Capital Partners LLP now owns 11,188 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 1,218 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 2,393,587 shares of the biopharmaceutical company’s stock valued at $268,512,000 after buying an additional 275,497 shares in the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.